Associate Director, Clinical Operations
Axsome Therapeutics Inc- Full Time
- Senior (5 to 8 years)
The Senior Director of Clinical Pharmacology should possess experience and expertise in matrixed leadership and team management, with a strong understanding of PK, PD, and immunogenicity properties of drugs and drug candidates. They require experience in clinical pharmacology strategy development from pre-IND through post-approval, including the design and implementation of clinical pharmacology studies, data analysis, and interaction with regulatory authorities. Additionally, they should have expertise in integrating clinical pharmacology knowledge with related disciplines like clinical, statistics, and regulatory affairs, and possess experience in population PK, PK/PD modeling and simulation, as well as preclinical PK/PD studies.
As the Senior Director, the individual will serve as the clinical pharmacologist for the company, providing strategic and scientific input across all clinical programs, leading the Clinical Pharmacology team accountable for the clinical pharmacology strategy, integrating clinical pharmacology knowledge with related disciplines, ensuring appropriate PK, PD, and PK/PD data analyses, collaborating with toxicologists and preclinical pharmacology scientists, ensuring adherence to timelines and budgets, developing and implementing new clinical pharmacology approaches, contributing to program strategy and study design, working closely with research and development teams, representing nonclinical and clinical pharmacology during meetings with regulatory authorities, and reviewing literature and publications to stay informed on regulatory developments. They will also create or guide summary documents and contribute to diligence assessments.
Develops treatments for neurodegenerative diseases
Amylyx Pharmaceuticals develops treatments for neurodegenerative diseases, focusing on conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's Disease (ALZ). Their main product, AMX0035, is currently undergoing clinical trials to assess its effectiveness. The CENTAUR ALS trial showed promising results for ALS patients, using a randomized, double-blind, placebo-controlled design to ensure reliable outcomes. They are also conducting the PEGASUS trial to evaluate AMX0035's safety and effectiveness in Alzheimer's patients. Unlike many competitors, Amylyx emphasizes community engagement and awareness campaigns, such as ALS Awareness Month, to educate the public and foster support for those affected by these diseases. The company's goal is to bring effective therapies to market that improve patient outcomes and enhance the quality of life for individuals suffering from neurodegenerative conditions.